Clinical trials: Hypertension ,Pregnancy
Pre-Eclampsia
Low Dose Aspirin for Prevention of Early Pregnancy Loss
Preeclampsia is a pregnancy-specific, multisystem disorder affecting 3% to 8% of pregnancies and remains a significant cause of maternal and neonatal morbidity and mortality worldwide.
- Trial name
- NCT06261203
- Testing
- Aspirin
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Egymedicalpedia
Hypertension, Early Diabetic Nephropathy
Antialbuminuric Effects of Valsartan and Lisinopril
Title: Antialbuminuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), open label, parallel group, 20 weeks follow-up.
- Trial name
- NCT00171600
- Testing
- VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension, Renal Dysfunction
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
This is a single-center, open-label, single-dose evaluation of 1 mg UT-15C SR pharmacokinetics, safety, and tolerability in subjects with normal, mild, moderate and end stage renal disease (ESRD; on dialysis).
- Trial name
- NCT01131845
- Testing
- UT-15C SR (treprostinil diethanolamine)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pregnant With Complication, Preeclampsia
Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test
This is Observational study, aiming to investigate the potentiality of cffDNA and cfRNA by a non-invasive test, in combination with clinical characteristics, to establish models for early screening and predicting high-risk…
- Conditions
- Pregnant With Complication, Preeclampsia, Preterm Birth, Gestational Diabetes
- Trial name
- NCT06385366
- Where
- Vietnam
- Volunteers
- 1,105 people
- Sponsor
- Gene Solutions
Pre-eclampsia
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine).
- Trial name
- NCT01566630
- Testing
- RLX030
- Where
- 5 sites in United States, Italy
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension, Erectile Dysfunction
A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects
To evaluate the effect of renal insufficiency on the pharmacokinetics of TPN171H tablets after single dose oral administration, so as to provide basis for formulating clinical medication plan for patients with renal…
- Trial name
- NCT05208814
- Testing
- TPN171H single dose
- Where
- 2 sites in China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Chronic Kidney Disease, Hypertension
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone.
- Conditions
- Chronic Kidney Disease, Hypertension, Hyperkalemia
- Trial name
- AMETHYST-DN (NCT01371747)
- Testing
- patiromer, losartan, spironolactone
- Where
- 43 sites in Croatia, Georgia and 3 more
- Volunteers
- 324 people
- Sponsor
- Relypsa, Inc.
Pre-Eclampsia
Evaluation of the Safety of Relaxin in Preeclampsia
The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia
- Trial name
- NCT00333307
- Testing
- recombinant human relaxin
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Preeclampsia
Molecular Screening Method for Preeclampsia (PREMOM)
Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening…
- Trial name
- PREMOM (NCT04990141)
- Testing
- Peripheral blood collection in cases group, Peripheral blood collection in control group
- Where
- 15 sites in Spain
- Volunteers
- 9,586 people
- Sponsor
- iPremom
Preeclampsia
KW-3357 Study in Patients With Early Onset Severe Preeclampsia
The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.
- Trial name
- NCT04182373
- Testing
- Antithrombin gamma, physiological saline
- Where
- 63 sites in Japan
- Volunteers
- 181 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Kidney Failure, Chronic, Renal Dialysis
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
The purpose of this this study is to investigate the clinical utility of renal denervation in the treatment of ESRD patients with refractory hypertension.
- Trial name
- NCT00753116
- Testing
- Renal Denervation with a catheter-based procedure
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medtronic Vascular
Pre-Eclampsia
DM199 for Pregnancy Complications
This entry was submitted in error by DiaMedica Therapeutics, Inc. and was not authorized by any of the trial Investigators or study sponsor (Stellenbosch University).
- Trial name
- NCT06875141
- Testing
- DM199
- Sponsor
- DiaMedica Therapeutics Inc
Hypertension, Renal Insufficiency, Chronic
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
The purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney…
- Trial name
- INSPIRE-CKD (NCT04162366)
- Testing
- Aprocitentan 25 mg
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pre-eclampsia
Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia
Preeclampsia is one of the leading causes of maternal and fetal death. It is a syndrome of pregnant women and is usually characterized by new onset of hypertension and proteinuria after 20 weeks of gestation.
- Trial name
- NCT07327255
- Testing
- EG-101
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Evergreen Therapeutics, Inc.
sFlt1 Mediated Preterm Preeclampsia, Preeclampsia
A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months
This study is a dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CBP-4888 in hospitalized participants with Preterm Preeclampsia receiving Standard of Care, Expectant…
- Conditions
- sFlt1 Mediated Preterm Preeclampsia, Preeclampsia, Preterm Preeclampsia
- Trial name
- NCT07282171
- Testing
- CBP-4888
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Comanche Biopharma
Hypertensive Disorders of Pregnancy (HDP), Maternal Health Care
Cost-Effectiveness of an mHealth Application in Pregnancy Care
Participants will be randomly assigned to either the intervention arm (mHealth application users) or the control arm, in which participants will record their data on paper or in Excel according to standard practice or the…
- Conditions
- Hypertensive Disorders of Pregnancy (HDP), Maternal Health Care, Mobile Health Technology (mHealth), Preeclampsia (PE)
- Trial name
- Penelope (NCT07621133)
- Testing
- mHealth application Penelope, Control
- Where
- Czechia
- Volunteers
- 166 people
- Sponsor
- Principal Engineering s.r.o.
Arterial Hypertension, Albuminuria
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al.
- Trial name
- NCT02376075
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- ikfe-CRO GmbH
Chronic Kidney Disease and Hypertension
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with…
- Trial name
- BaxDuo-Baltic (NCT07222917)
- Testing
- Baxdrostat/dapagliflozin
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
High Cardiovascular Risk, Hypertension
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
- Trial name
- KARDIA-3 (NCT06272487)
- Testing
- Zilebesiran
- Where
- 195 sites in United States, Australia and 4 more
- Volunteers
- 375 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension, Diabetes Mellitus, Type 2
INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria
A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy…
- Trial name
- NCT01398423
- Testing
- Active Control, INV-144
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- InVasc Therapeutics, Inc.